Robert P. Bowser, Ph.D.
Phoenix, Arizona, United States
1K followers
500+ connections
About
Chief Scientific Officer of the Barrow Neurological Institute and St. Joseph's Hospital…
Activity
Experience
Education
Publications
-
Artificial intelligence in neurodegenerative disease research: Use of IBM Watson to identify additional RNA binding proteins altered in amyotrophic lateral sclerosis
Acta Neuropathologica
Numerous RNA-binding proteins (RBPs) have been shown to be altered in ALS, with mutations in 11 RBPs causing familial forms of the disease, and 6 more RBPs showing abnormal expression/distribution in ALS albeit without any known mutations. RBP dysregulation is widely accepted as a contributing factor in ALS pathobiology. There are at least 1542 RBPs in the human genome; therefore, other unidentified RBPs may also be linked to the pathogenesis of ALS. We used IBM Watson® to sieve through all…
Numerous RNA-binding proteins (RBPs) have been shown to be altered in ALS, with mutations in 11 RBPs causing familial forms of the disease, and 6 more RBPs showing abnormal expression/distribution in ALS albeit without any known mutations. RBP dysregulation is widely accepted as a contributing factor in ALS pathobiology. There are at least 1542 RBPs in the human genome; therefore, other unidentified RBPs may also be linked to the pathogenesis of ALS. We used IBM Watson® to sieve through all RBPs in the genome and identify new RBPs linked to ALS (ALS-RBPs). IBM Watson extracted features from published literature to create semantic similarities and identify new connections between entities of interest. IBM Watson analyzed all published abstracts of previously known ALS-RBPs, and applied that text-based knowledge to all RBPs in the genome, ranking them by semantic similarity to the known set. We then validated the Watson top-ten-ranked RBPs at the protein and RNA levels in tissues from ALS and non-neurological disease controls, as well as in patient-derived induced pluripotent stem cells.
-
ALS associated mutations in Matrin 3 alter protein-protein interactions and impede mRNA nuclear export
Nature
Mutations in Matrin 3 have recently been linked to ALS, though the mechanism that induces disease in these patients is unknown. To define the protein interactome of wild-type and ALS-linked MATR3 mutations, we performed immunoprecipitation followed by mass spectrometry using NSC-34 cells expressing human wild-type or mutant Matrin 3. Gene ontology analysis identified a novel role for Matrin 3 in mRNA transport centered on proteins in the TRanscription and EXport (TREX) complex, known to…
Mutations in Matrin 3 have recently been linked to ALS, though the mechanism that induces disease in these patients is unknown. To define the protein interactome of wild-type and ALS-linked MATR3 mutations, we performed immunoprecipitation followed by mass spectrometry using NSC-34 cells expressing human wild-type or mutant Matrin 3. Gene ontology analysis identified a novel role for Matrin 3 in mRNA transport centered on proteins in the TRanscription and EXport (TREX) complex, known to function in mRNA biogenesis and nuclear export. ALS-linked mutations in Matrin 3 led to its re-distribution within the nucleus, decreased co-localization with endogenous Matrin 3 and increased co-localization with specific TREX components. Expression of disease-causing Matrin 3 mutations led to nuclear mRNA export defects of both global mRNA and more specifically the mRNA of TDP-43 and FUS. Our findings identify a potential pathogenic mechanism attributable to MATR3 mutations and further link cellular transport defects to ALS.
-
Immunoprecipitation and Mass Spectrometry Defines an Extensive RBM45 Protein-Protein Interaction Network
Brain Research
The pathological accumulation of RNA-binding proteins (RBPs) within inclusion bodies is a hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). RBP aggregation results in both toxic gain and loss of normal function. Determining the protein binding partners and normal functions of disease-associated RBPs is necessary to fully understand molecular mechanisms of RBPs in disease. Herein, we characterized the protein-protein interactions (PPIs) of RBM45, a RBP…
The pathological accumulation of RNA-binding proteins (RBPs) within inclusion bodies is a hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). RBP aggregation results in both toxic gain and loss of normal function. Determining the protein binding partners and normal functions of disease-associated RBPs is necessary to fully understand molecular mechanisms of RBPs in disease. Herein, we characterized the protein-protein interactions (PPIs) of RBM45, a RBP that localizes to inclusions in ALS/FTLD. Using immunoprecipitation coupled to mass spectrometry (IP-MS), we identified 132 proteins that specifically interact with RBM45 within HEK293 cells. Select PPIs were validated by immunoblot and immunocytochemistry, demonstrating that RBM45 associates with a number of other RBPs primarily via RNA-dependent interactions in the nucleus. Analysis of the biological processes and pathways associated with RBM45-interacting proteins indicates enrichment for nuclear RNA processing/splicing via association with hnRNP proteins and cytoplasmic RNA translation via eiF2 and eiF4 pathways. Moreover, several other ALS-linked RBPs, including TDP-43, FUS, Matrin-3, and hnRNP-A1, interact with RBM45, consistent with prior observations of these proteins within intracellular inclusions in ALS/FTLD. Taken together, our results define a PPI network for RBM45, suggest novel functions for this protein, and provide new insights into the contributions of RBM45 to neurodegeneration in ALS/FTLD.
-
Label-free LC-MS/MS proteomic analysis of cerebrospinal fluid identifies protein/pathway alterations and candidate biomarkers for amyotrophic lateral sclerosis
Journal of Proteome Research
Analysis of the cerebrospinal fluid (CSF) proteome has proven valuable to the study of neurodegenerative disorders. To identify new protein/pathway alterations and candidate biomarkers for amyotrophic lateral sclerosis (ALS), we performed comparative proteomic profiling of CSF from sporadic ALS (sALS), healthy control (HC), and other neurological disease (OND) subjects using label-free liquid chromatography-tandem mass spectrometry (LC-MS/MS). A total of 1,712 CSF proteins were detected and…
Analysis of the cerebrospinal fluid (CSF) proteome has proven valuable to the study of neurodegenerative disorders. To identify new protein/pathway alterations and candidate biomarkers for amyotrophic lateral sclerosis (ALS), we performed comparative proteomic profiling of CSF from sporadic ALS (sALS), healthy control (HC), and other neurological disease (OND) subjects using label-free liquid chromatography-tandem mass spectrometry (LC-MS/MS). A total of 1,712 CSF proteins were detected and relatively quantified by spectral counting. Levels of several proteins with diverse biological functions were significantly altered in sALS samples. Enrichment analysis was used to link these alterations to biological pathways, which were predominantly related to inflammation, neuronal activity, and extracellular matrix regulation. We then used our CSF proteomic profiles to create a support vector machines classifier capable of discriminating training set ALS from non-ALS (HC and OND) samples. Four classifier proteins, WD repeat containing protein 63, SPARC-like protein 1, cell adhesion molecule 3, and amyloid-like protein 1, were identified by feature selection and externally validated. The resultant classifier distinguished ALS from non-ALS samples with 83% sensitivity and 100% specificity in an independent test set. Collectively, our results illustrate the utility of CSF proteomic profiling for identifying ALS protein/pathway alterations and candidate disease biomarkers.
-
The RNA binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients
Acta Neuropathologica
RNA binding protein pathology now represents one of the best characterized pathologic features of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration patients with TDP-43 or FUS pathology (FTLD-TDP and FTLD-FUS). Using liquid chromatography tandem mass spectrometry, we identified altered levels of the RNA binding motif 45 (RBM45) protein in the cerebrospinal fluid (CSF) of ALS patients. This protein contains sequence similarities to TAR DNA binding protein 43 (TDP-43)…
RNA binding protein pathology now represents one of the best characterized pathologic features of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration patients with TDP-43 or FUS pathology (FTLD-TDP and FTLD-FUS). Using liquid chromatography tandem mass spectrometry, we identified altered levels of the RNA binding motif 45 (RBM45) protein in the cerebrospinal fluid (CSF) of ALS patients. This protein contains sequence similarities to TAR DNA binding protein 43 (TDP-43) and Fused-In-Sarcoma (FUS) that are contained in cytoplasmic inclusions of ALS and FTLD-TDP or FTLD-FUS patients. To further characterize RBM45, we first verified the presence of RBM45 in CSF and spinal cord tissue extracts of ALS patients by immunoblot. We next used immunohistochemistry to examine the subcellular distribution of RBM45 and observed in a punctate staining pattern within nuclei of neurons and glia in the brain and spinal cord. We also detected RBM45 cytoplasmic inclusions in 91% of ALS, 100% of FTLD-TDP and 75% of Alzheimer’s disease (AD) cases. The most extensive RBM45 pathology was observed in patients that harbor the C9ORF72 hexanucleotide repeat expansion. These RBM45 inclusions were observed in spinal cord motor neurons, glia and neurons of the dentate gyrus. By confocal microscopy, RBM45 co-localizes with ubiquitin and TDP-43 in inclusion bodies. In neurons containing RBM45 cytoplasmic inclusions we often detected the protein in a punctate pattern within the nucleus that lacked either TDP-43 or ubiquitin. We identified RBM45 using a proteomic screen of CSF from ALS and control subjects for candidate biomarkers, and link this RNA binding protein to inclusion pathology in ALS, FTLD-TDP and AD.
-
Outcome of lumbar epidural steroid injection is predicted by assay of a complex of fibronectin and aggrecan from epidural lavage
Spine
A single-center, prospective, consecutive case series of patients undergoing epidural lavage before the treatment of radiculopathy due to lumbar disc herniation.
Other authorsSee publication -
Combination of neurofilament heavy chain and complement c3 as CSF biomarkers for ALS
Journal of Neurochemistry, 117: 527-537
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive and ultimately fatal neurodegenerative disease with an average survival of 3 years from symptom onset. Rapid and conclusive early diagnosis is essential if interventions with disease-modifying therapies are to be successful. Cytoskeletal modification and inflammation are known to occur during the pathogenesis of ALS. We measured levels of cytoskeletal proteins and inflammatory markers in the cerebrospinal fluid (CSF) of ALS…
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive and ultimately fatal neurodegenerative disease with an average survival of 3 years from symptom onset. Rapid and conclusive early diagnosis is essential if interventions with disease-modifying therapies are to be successful. Cytoskeletal modification and inflammation are known to occur during the pathogenesis of ALS. We measured levels of cytoskeletal proteins and inflammatory markers in the cerebrospinal fluid (CSF) of ALS, disease controls and healthy subjects. We determined threshold values for each protein that provided the optimal sensitivity and specificity for ALS within a training set, as determined by receiver operating characteristic (ROC) analysis. Interestingly, the optimal assay was a ratio of the levels for phosphorylated neurofilament heavy chain and complement C3 (pNFH/C3). We next applied this assay to a separate test set of CSF samples to verify our results. Overall, the predictive pNFH/C3 ratio identified ALS with 87.3% sensitivity and 94.6% specificity in a total of 71 ALS subjects, 52 disease control subjects and 40 healthy subjects. In addition, the level of CSF pNFH correlated with survival of ALS patients. We also detected increased pNFH in the plasma of ALS patients and observed a correlation between CSF and plasma pNFH levels within the same subjects. These findings support large-scale prospective biomarker studies to determine the clinical utility of diagnostic and prognostic signatures in ALS.
-
Proposed BioRepository platform solution for the ALS research community
Amyotrophic Lateral Sclerosis
ALS is a rare disorder whose cause and pathogenesis is largely unknown. There is a recognized need to develop biomarkers for ALS to better understand the disease, expedite diagnosis and to facilitate therapy development. Collaboration is essential to obtain a sufficient number of samples to allow statistically meaningful studies.
Other authorsSee publication -
Discovery and verification of amyotrophic lateral sclerosis biomarkers by mass spectrometry based proteomics
Muscle & Nerve 42: 104-111
Recent studies using mass spectrometry have
discovered candidate biomarkers for amyotrophic lateral sclerosis
(ALS). However, those studies utilized small numbers of
ALS and control subjects. Additional studies using larger subject
cohorts are required to verify these candidate biomarkers.
Cerebrospinal fluid (CSF) samples from 100 patients with ALS,
100 disease control, and 41 healthy control subjects were
examined by mass spectrometry. Sixty-one mass spectral
peaks…Recent studies using mass spectrometry have
discovered candidate biomarkers for amyotrophic lateral sclerosis
(ALS). However, those studies utilized small numbers of
ALS and control subjects. Additional studies using larger subject
cohorts are required to verify these candidate biomarkers.
Cerebrospinal fluid (CSF) samples from 100 patients with ALS,
100 disease control, and 41 healthy control subjects were
examined by mass spectrometry. Sixty-one mass spectral
peaks exhibited altered levels between ALS and controls. Mass
peaks for cystatin C and transthyretin were reduced in ALS,
whereas mass peaks for posttranslational modified transthyretin
and C-reactive protein (CRP) were increased. CRP levels were
5.84 6 1.01 ng/ml for controls and 11.24 6 1.52 ng/ml for ALS
subjects, as determined by enzyme-linked immunoassay. This
study verified prior mass spectrometry results for cystatin C
and transthyretin in ALS. CRP levels were increased in the
CSF of ALS patients, and cystatin C level correlated with survival
in patients with limb-onset disease. Our biomarker panel
predicted ALS with an overall accuracy of 82%.
Patents
-
Biomarkers for the diagnosis of ALS
Issued United States 8,465,727
-
Biomarkers for motor neuron disease
Issued United States 7,858,071
This invention describes proteins within the cerebrospinal fluid that can be used for the diagnosis of amyotrophic lateral sclerosis (ALS)
-
Modulation of the neuroendocrine system as a therapy for motor neuron disease
Issued United States 7,572,596
The invention describes a method to diagnose a patient with amyotrophic lateral sclerosis (ALS) and provide treatment based on proteins of the neuroendocrine system.
Other inventors
Honors & Awards
-
Sean M. Healey International Prize for Innovation in ALS
Sean M. Healey Center for ALS
-
IBM Big Data and Analytics Hero
IBM
-
Sheila Essey Award for ALS Research
American Academy of Neurology (AAN)
More activity by Robert P.
Monica M. Bertagnolli, M.D., started today as the 17th NIH Director. She is the first surgeon and the second woman to hold the position. Nominated by…
Liked by Robert P. Bowser, Ph.D.
Proud to play a small role in this new public-private partnership, multi-institutional ALS Clinical Research Consortium with goal of giving access to…
Liked by Robert P. Bowser, Ph.D.
Pleased and proud to have received my doctoral degree in business from the University of Florida. Finally made it. As always, "the journey is the…
Liked by Robert P. Bowser, Ph.D.
Incredibly proud of you Curtis Chalmers, CIC, RPLU for all the years of dedication and hard work you've put in, along with the many partners turned…
Liked by Robert P. Bowser, Ph.D.
Thanks for the support of outstanding scientists, physicians, physician-scientists and patients that have made this a meaningful journey and enabled…
Liked by Robert P. Bowser, Ph.D.
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More